Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
N/A
Synonyms :
glecaprevir
Class :
antiviral agents
Brand Name :
N/A
Synonyms :
glecaprevir
Class :
antiviral agents
Safety and efficacy were not establishedÂ
Refer to the adult dosing regimenÂ
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration of ivacaftor/tezacaftor
may enhance the serum concentration
may enhance the serum concentration
may enhance the serum concentration
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration when combined with nifedipine
may increase the serum concentration of abemaciclib
may increase the level of serum concentration of adagrasib
may increase or decrease the activity of this enzyme when combined with sparsentan
May enhance the serum concentration when combined with levomilnacipran
may enhance the serum concentration when combined with upadacitinib
may enhance the serum concentration when combined with tolvaptan
It may enhance serum concentration when combined with CYP3A4 Inhibitors (Moderate)
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Zanubrutinib
may enhance the serum concentration when combined
may enhance the concentration of serum when combined with ubrogepant
may enhance the serum concentrations of the active metabolites
may enhance the serum concentration when combined
may enhance the concentration of serum when combined with istradefylline
may enhance the concentration of serum when combined with alfentanil
may enhance the concentration of serum when combined with astemizole
may enhance the concentration of serum when combined with avanafil
may enhance the concentration of serum when combined with brigatinib
may enhance the concentration of serum when combined with bromocriptine
budesonide inhaled/formoterol/glycopyrrolate inhaledÂ
may enhance the concentration of serum when combined with budesonide
may enhance the concentration of serum when combined with cilostazol
may enhance the concentration of serum when combined with cisapride
may enhance the concentration of serum when combined with cobimetinib
may enhance the concentration of serum when combined with colchicine
may enhance the concentration of serum when combined with dapoxetine
may enhance the concentration of serum when combined with daridorexant
may enhance the concentration of serums when combined with deflazacort
may enhance the concentration of serum when combined with eliglustat
may enhance the concentration of serum when combined with encorafenib
may enhance the concentration of serum when combined with entrectinib
may enhance the concentration of serum when combined with eplerenone
may enhance the concentration of serum when combined with fentanyl
may enhance the concentration of serum when combined with guanfacine
may enhance the concentration of serum when combined with ibrutinib
may enhance the concentration of serum when combined with elacestrant
may enhance the QTc-prolonging effect of each other when combined
lurasidone: they may enhance the serum concentration of CYP3A4 Inhibitors
CYP3A4 Inhibitors: they may enhance the serum concentration of mavacamten
pemigatinib: they may enhance the serum concentration of CYP3A4 Inhibitors
omaveloxolone: they may enhance the serum concentration of CYP3A4 Inhibitors
pexidartinib: they may enhance the serum concentration of CYP3A4 Inhibitors
selpercatinib: they may enhance the serum concentration of CYP3A4 Inhibitors
selumetinib: they may enhance the serum concentration of CYP3A4 Inhibitors
sonidegib: they may enhance the serum concentration of CYP3A4 Inhibitors
tazemetostat: they may enhance the serum concentration of CYP3A4 Inhibitors
vardenafil: they may enhance the serum concentration of CYP3A4 Inhibitors
venetoclax: they may enhance the serum concentration of CYP3A4 Inhibitors
voclosporin: they may enhance the serum concentration of CYP3A4 Inhibitors
may enhance the risk of side effects when combined
cimetropium: they may enhance the serum concentration of CYP3A4 Inhibitors
may increase the levels of serum concentration of ergot derivatives
may enhance the serum concentration when combined with hormonal contraceptives
may enhance the serum concentration when combined with hormonal contraceptives
may enhance the serum concentration when combined with hormonal contraceptives
may enhance the serum concentration when combined with hormonal contraceptives
may enhance the serum concentration when combined with hormonal contraceptives
may enhance the serum concentration when combined with hormonal contraceptives
may enhance the serum concentration when combined with hormonal contraceptives
they decrease the concentration of active metabolites of roflumilast in the serum
it increases the concentration of CYP3A4 substrates in the serum
it increases the concentration of CYP3A4 substrates in serum
may increase the levels of serum concentration of eletriptan
may increase the serum concentration of acalabrutinib
CYP3A4 inhibitors increase the concentration of active metabolites of simvastatin in the serum
may enhance the serum concentration of simeprevir
may enhance the serum concentration
may enhance the serum concentration of fostemsavir
may enhance the serum concentrations of flibanserin
may diminish the serum concentration when combined with nintedanib
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Sertindole
CYP3A4 Inhibitors (Moderate) may decrease serum concentrations when combined with the active metabolite(s) when combined with Infigratinib
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with methysergide
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Pacritinib
may enhance serum concentrations of the active metabolites
may enhance the serum concentration when combined
may enhance the concentration of serum when combined with pimozide
The serum concentration of alfuzosin can be increased by strong CYP3A4 inhibitors
may enhance the serum concentration when combined
may diminish the concentration of serum when combined with CYP3A4 substrates
may enhance the concentration of serum when combined with ergot derivatives
may enhance the concentration of serum when combined with ergot derivatives
may enhance the concentration of serum when combined with aprepitant
may enhance the concentration of serum when combined with asunaprevir
may enhance the concentration of serum when combined with bosutinib
may enhance the concentration of serum when combined with budesonide
may enhance the concentration of serum when combined with isavuconazonium sulfate
may enhance the concentration of serum when combined with domperidone
may enhance the concentration of serum when combined with fosaprepitant
may enhance the concentration of serum when combined with ivabradine
may increase the serum concentration of each other when combined
nisoldipine: they may enhance the serum concentration of CYP3A4 Inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
CYP3A4 inhibitors (Strong) may increase the serum concentration of estrogen related drugs
bazedoxifene/conjugated estrogens
CYP3A4 inhibitors (Strong) may increase the serum concentration of estrogen related drugs
CYP3A4 inhibitors (Strong) may increase the serum concentration of estrogen related drugs
synthetic conjugated estrogens, a
CYP3A4 inhibitors (Strong) may increase the serum concentration of estrogen related drugs
synthetic conjugated estrogens, b
CYP3A4 inhibitors (Strong) may increase the serum concentration of estrogen related drugs
may increase the serum concentration of ergot derivatives
may increase the serum concentration of ergot derivatives
may increase the serum concentration of ergot derivatives
may increase the serum concentration of ergot derivatives
may increase the serum concentration of ergot derivatives
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
bazedoxifene/conjugated estrogens
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of hormonal contraceptives
may increase the levels of serum concentration of hormonal contraceptives
may increase the levels of serum concentration of hormonal contraceptives
may increase the levels of serum concentration of hormonal contraceptives
synthetic conjugated estrogens, a
may increase the serum concentration
synthetic conjugated estrogens, b
may increase the serum concentration
may increase the serum concentration
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
acetaminophen and phenyltoloxamine
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
acetaminophen and phenyltoloxamine
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may enhance the levels of serum concentration
may enhance the levels of serum concentration
may enhance the levels of serum concentration
may enhance the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
it increases the concentration of CYP3A4 substrates in the serum
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
When glecaprevir is used together with ouabain, this leads to reduction in glecaprevir excretion
it increases the concentration of CYP3A4 substrates in the serum
hydrocodone/​chlorpheniramine/​pseudoephedrineÂ
may diminish the serum concentration
it increases the concentration of alosetron in the serum
they decrease the concentration of linagliptin in the serum
may increase the serum concentration of clozapine
may increase the levels of serum concentrations of cariprazine
may enhance the serum concentration
may increase the serum concentration of zopiclone
may enhance the serum concentration of CYP3A4 inhibitor
may increase the toxic effect of opioid agonists
may enhance the serum concentration
may diminish serum concentrations when combined with doxercalciferol
may enhance the serum concentrations
may increase the level of serum concentration of itraconazole
CYP3A4 inhibitors increase the concentration of finerenone in the serum
CYP3A4 inhibitors increase the concentration of tacrolimus in the serum
may increase the serum concentration of pimecrolimus
may increase the serum concentration
may reduce the effect of zavegepant
may enhance the serum concentration of dexamethasone
may increase the QTc prolonging effect of QTc prolonging agents
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Vilazodone
It may enhance serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may increase serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance the serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may increase the serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance the serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance the serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance the serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance the serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance the serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance the serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance the serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance the serum concentration when combined with CYP3A4 Inhibitors (Moderate)
may enhance the serum concentration when combined with ziprasidone
methylprednisolone hemisuccinateÂ
may increase the levels of serum concentration
may decrease the levels of serum concentration
It may enhance the serum concentration when combined with dexamethasone
may enhance the concentration of serum when combined with alprazolam
may enhance the concentration of serum when combined with carbamazepine
may enhance the concentration of serum when combined with cyclosporine
may enhance the concentration of serum when combined with dofetilide
may enhance the concentration of serum when combined with ixabepilone
may enhance the concentration of serum when combined with midazolam
may enhance the concentration of serum when combined with nimodipine
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
bazedoxifene/conjugated estrogens
may increase the levels of serum concentration
synthetic conjugated estrogens, a
may increase the levels of serum concentration
synthetic conjugated estrogens, b
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
buprenorphine,long-acting injectionÂ
may enhance the serum concentration of Buprenorphine
may enhance the concentration of serum when combined with sirolimus
It may enhance the serum concentration when combined with CYP3A4 Inhibitors
The serum concentration of amlodipine can be increased by strong inhibitors of CYP3A4
The use of strong CYP3A4 inhibitors may elevate the serum concentration of benidipine
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
may enhance the serum concentration when combined with dexamethasone
fusidic acid and betamethasoneÂ
may enhance the serum concentration when combined
may enhance the concentration of serum when combined with alitretinoin
may enhance the concentration of serum when combined with amiodarone
may enhance the concentration of serum when combined with aripiprazole
may enhance the concentration of serum when combined with aripiprazole lauroxil
may enhance the concentration of serum when combined with atogepant
may enhance the concentration of serum when combined with atorvastatin
may enhance the concentration of serum when combined with avacopan
may enhance the concentration of serum when combined with axitinib
may enhance the concentration of serums when combined with bedaquiline
benzhydrocodone/acetaminophenÂ
may enhance the concentration of serum when combined with benzhydrocodone
may enhance the concentration of serum when combined with bortezomib
may enhance the concentration of serum when combined with brexpiprazole
may enhance the concentration of serum when combined with buprenorphine
may enhance the serum concentration when combined
may enhance the serum concentration when combined
may diminish the serum concentration of each other when combined
may enhance the concentration of serum when combined with methylprednisolone
framycetin, dexamethasone, and gramicidinÂ
may enhance the serum concentration when combined
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
clindamycin: they may enhance the serum concentration of CYP3A4 Inhibitors
copanlisib: they may enhance the serum concentration of CYP3A4 Inhibitors
conivaptan: they may enhance the serum concentration of CYP3A4 Inhibitors
crizotinib: they may enhance the serum concentration of CYP3A4 Inhibitors
darifenacin: they may enhance the serum concentration of CYP3A4 Inhibitors
erythromycin: they may enhance the serum concentration of CYP3A4 inhibitors
fluticasone furoate: they may enhance the serum concentration of CYP3A4 inhibitors
halofantrine: they may enhance the serum concentration of CYP3A4 inhibitors
isradipine: they may enhance the serum concentration of CYP3A4 inhibitors
levamlodipine: they may enhance the serum concentration of CYP3A4 Inhibitors
naldemedine: they may enhance the serum concentration of CYP3A4 Inhibitors
nilotinib: they may enhance the serum concentration of CYP3A4 Inhibitors
oliceridine: they may enhance the serum concentration of CYP3A4 Inhibitors
palovarotene: they may enhance the serum concentration of CYP3A4 Inhibitors
panobinostat: they may enhance the serum concentration of CYP3A4 Inhibitors
piperaquine: they may enhance the serum concentration of CYP3A4 Inhibitors
pirtobrutinib: they may enhance the serum concentration of CYP3A4 Inhibitors
quetiapine: they may enhance the serum concentration of CYP3A4 Inhibitors
ribociclib: they may enhance the serum concentration of CYP3A4 Inhibitors
rifabutin: they may enhance the serum concentration of CYP3A4 Inhibitors
saxagliptin: they may enhance the serum concentration of CYP3A4 Inhibitors
silodosin: they may enhance the serum concentration of CYP3A4 Inhibitors
tadalafil: they may enhance the serum concentration of CYP3A4 Inhibitors
terfenadine: they may enhance the serum concentration of CYP3A4 Inhibitors
udenafil: they may enhance the serum concentration of CYP3A4 Inhibitors
ulipristal: they may enhance the serum concentration of CYP3A4 Inhibitors
valbenazine: they may enhance serum concentrations of CYP3A4 Inhibitors
vemurafenib: they may enhance the serum concentration of CYP3A4 Inhibitors
vorapaxar: they may enhance the serum concentration of CYP3A4 Inhibitors
finerenone: they may enhance the serum concentration of CYP3A4 Inhibitors
fosphenytoin: they may enhance the serum concentration of CYP3A4 Inhibitors
lidocaine: they may enhance the serum concentration of CYP3A4 Inhibitors
porfimer: they may enhance the serum concentration of CYP3A4 Inhibitors
phenytoin: they may enhance the serum concentration of CYP3A4 Inhibitors
aliskiren: they may enhance the serum concentration of CYP3A4 Inhibitors
voriconazole: they may enhance the serum concentration of CYP3A4 Inhibitors
tizanidine: they may enhance the serum concentration of CYP3A4 Inhibitors
may enhance the serum concentration of each other when combined
betamethasone + salicylic acidÂ
may enhance the serum concentration of each other when combined
eluxadoline: they may enhance the serum concentration of CYP3A4 Inhibitors
oxatomide: they may enhance the serum concentration of CYP3A4 Inhibitors
revefenacin: they may enhance the serum concentration of CYP3A4 Inhibitors
tiotropium: they may enhance the serum concentration of CYP3A4 Inhibitors
glucagon: they may enhance the serum concentration of CYP3A4 Inhibitors
itopride: they may enhance the serum concentration of CYP3A4 Inhibitors
mianserin: they may enhance the serum concentration of CYP3A4 Inhibitors
topiramate: they may enhance the serum concentration of CYP3A4 Inhibitors
may enhance the serum concentration of CYP3A4 inhibitor
may enhance the serum concentration of CYP3A4 inhibitor
may enhance the serum concentration of CYP3A4 inhibitor
may enhance the serum concentration of CYP3A4 inhibitor
may enhance the serum concentration of CYP3A4 inhibitor
ketamine: it may increase the risk of adverse effects with CYP3A4 inhibitors
decamethonium: it may increase the risk of adverse effects with CYP3A4 inhibitors
ketamine: it may increase the risk of adverse effects with CYP3A4 inhibitors
levobetaxolol: it may increase the risk of adverse effects with CYP3A4 inhibitors
mefloquine: it may increase the risk of adverse effects with CYP3A4 inhibitors
memantine: it may increase the risk of adverse effects with CYP3A4 inhibitors
CYP3A4 inhibitors increase the concentration of sirolimus in the serum
CYP3A4 inducers increase the concentration of buspirone in the serum
almotriptan serum concentration may also be increased by CYP3A4 inhibitors (strong)
Actions and spectrum:Â
Action:Â
Glecaprevir is a direct-acting antiviral (DAA) agent that interferes with the replication process of the hepatitis C virus. Specifically, it inhibits the NS3/4A protease enzyme that is essential for virus to replicate. By blocking this enzyme, glecaprevir helps to reduce the viral load in the body, suppressing the replication of the hepatitis C virus.Â
Spectrum:Â
The combination of glecaprevir and pibrentasvir is notable for its broad-spectrum activity against multiple genotypes of the hepatitis C virus. It is effective against genotypes 1 through 6, making it a pangenotypic treatment option. This is important because HCV is genetically diverse, with different genotypes requiring different treatment approaches. The pangenotypic nature of glecaprevir and pibrentasvir makes it a versatile and convenient option for treating various HCV infections.Â
Frequency not definedÂ
AngioedemaÂ
DiarrhoeaÂ
HeadacheÂ
NauseaÂ
increased Serum bilirubinÂ
AstheniaÂ
FatigueÂ
HyperbilirubinaemiaÂ
PruritusÂ
Transient ischaemic attackÂ
Black Box Warning:Â
there were no specific black box warnings listed for glecaprevir.Â
Contraindication/Caution:Â
Contraindication:Â
Caution:Â
Comorbidities:Â
Pregnancy consideration: pregnancy category: not assignedÂ
Lactation: excreted into human milk: unknown Â
Pregnancy category:Â
Pharmacology:Â
Glecaprevir is a direct-acting antiviral medication used in chronic hepatitis C virus (HCV) infections. It belongs to the class of NS3/4A protease inhibitors. The pharmacology of glecaprevir involves its potent inhibition of the NS3/4A protease enzyme, a crucial component in the replication of the hepatitis C virus.
By targeting this protease, glecaprevir disrupts the viral life cycle, preventing virus from replicating and leading to a reduction in viral load. Glecaprevir is often used in combination with other antiviral agents, such as pibrentasvir, to enhance its efficacy and cover a broad spectrum of HCV genotypes.
The medication is typically administered orally, and its pharmacokinetic properties contribute to its effectiveness in achieving sustained virologic response with chronic HCV infections. Â
Pharmacodynamics:Â
Pharmacokinetics:Â
Administration:Â
Patient information leafletÂ
Generic Name: glecaprevirÂ
Pronounced: (gleh-ka-PREV-ir)Â Â
Why do we use glecaprevir?Â
Glecaprevir is a medication primarily used to treat chronic hepatitis C virus (HCV) infections. It is often prescribed as part of a combination therapy with another antiviral agent, such as pibrentasvir. The combination of glecaprevir and pibrentasvir is known for its pangenotypic activity, meaning it is effective against multiple genotypes of HCV.
This makes glecaprevir a versatile treatment option for a broad range of patients with different HCV genotypes. The medication is indicated for both treatment-naive individuals and those who have previously failed treatment with other antiviral medications.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
